Ireland
--:--IST
Recruiting Observational

Neuroendocrine Carcinomas: Patient Journey And Treatment Outcomes In Latin America

NCT07192991 · tracked via the Priya Life Science Brazil tracker
Phase
Observational
Started
2025-12-16
Last updated
2026-09-08

Condition(s) studied

Neuroendocrine CarcinomasLung Neuroendocrine Carcinoma

Investigational drug(s) / intervention(s)

Observational study

Observational study: This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.

Study summary

This observational, retrospective study aims to understand the treatment patterns and outcomes of patients with pulmonary and extra-pulmonary neuroendocrine carcinomas (NEC) in Latin America (Brazil, Mexico, Argentina, and Peru). The research will collect data from medical records to analyze factors like patient demographics, diagnosis methods, tumor characteristics, treatment approaches, and disease progression. The study is non-interventional, meaning patient care will follow standard clinical practice, with data gathered via an electronic system.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * ≥18 years old * Diagnosed between August 2014 and August 2024 with one of the following: * Extrapulmonary Neuroendocrine Carcinoma (EP-NEC) * Large-cell neuroendocrine carcinoma (LCNEC) or mixed * Small Cell Lung Cancer (SCLC) or mixed * Adequate and accessible medical records for data collection * Tumor block collected from 2014 onwards Exclusion Criteria: * Patients with active, concurrent malignancies at the time of NEC diagnosis, except for non-invasive cancers like basal cell carcinoma or squamous cell carcinoma of the skin, or in situ cervical cancer. * Patients or their legal representatives unwilling or unable to provide informed consent (if needed per ethics committee).

Primary outcome measure(s)

  • Patterns of Initial Cancer Treatment: number of participants treated within vs. outside high-volume sites and associated treatment characteristics — Throughout the study period, an average of 24 months
    Treatment patterns will be analyzed descriptively using tables and graphs to illustrate the distribution of patients receiving initial cancer treatment within versus outside high-volume treatment centers. Key characteristics of the initial treatment will be assessed.
  • Event-free survival (EFS) — Throughout the study period, an average of 24 months
    defined as time from diagnosis until relapse, death, or definitive failure of treatment strategy that implicates failure of curative-intent treatment \[for patients treated with curative intent\]. Participants who are lost to follow up or reach the study end will be censored at their last date of contact.
  • Time to treatment failure (TTF) — Throughout the study period, an average of 24 months
    in first and second-line: defined as time from first dose of treatments until date of discontinuation of treatment for any reason, including progression of disease, treatment toxicity, and death. Participants who are lost to follow up or reach the study end will be censored at their last date of contact
  • Progression-free survival (PFS) — Throughout the study period, an average of 24 months
    defined as time from treatment initiation until progression or death \[for patients treated with palliative intent\]. Participants who are lost to follow up or reach the study end will be censored at their last date of contact.
  • Overall survival — Throughout the study period, an average of 24 months
    \[according to disease stage/setting\], defined as time from initial diagnosis until date of death from any cause. Participants who are lost to follow up or reach the study end will be censored at their last date of contact.
  • Frequency of DLL-3 immunohistochemistry expression — After the end of recruitment, an average of 1 year
    Rate of patients with DLL3 expression in extra-pulmonary and pulmonary NEC by IHC \[stratified by tumor primary site\]

Trial sites (19)

FacilityCityRegionStatus
Hospital Británico de Buenos Aires Buenos Aires Buenos Aires Recruiting
Hospital de Gastroenterología Carlos Bonorino Udaondo Buenos Aires Buenos Aires Recruiting
Instituto Alexander Fleming Buenos Aires Buenos Aires Recruiting
Hospital Evangélico de Cachoeiro de Itapemirim - Centro de Pesquisas Clínicas em Oncologia (CPCO) Cachoeiro de Itapemirim Espírito Santo Active Not Recruiting
Clínica Prognóstica - Centro de Pesquisa Clínica Onconeo Campo Grande Mato Grosso do Sul Active Not Recruiting
Oncocentro de Minas Gerais (Oncoclínicas) Belo Horizonte Minas Gerais Active Not Recruiting
IOP Pesquisa - Instituto de Oncologia do Paraná Curitiba Paraná Active Not Recruiting
HCL - Hospital do Câncer de Londrina Londrina Paraná Active Not Recruiting
INCA - Instituto Nacional de Câncer Rio de Janeiro Rio de Janeiro Active Not Recruiting
HUOL - Hospital Universitário Onofre Lopes da UFRN Natal Rio Grande do Norte Active Not Recruiting
Liga Norte Riograndense Contra o Câncer Natal Rio Grande do Norte Active Not Recruiting
HMV - Hospital Moinhos de Vento Porto Alegre Rio Grande do Sul Active Not Recruiting
Futtura Oncologia - Hub de Pesquisa Clínica Porto Alegre Rio Grande do Sul Active Not Recruiting
ANIMI - Unidade de Tratamento Oncológico Lages Santa Catarina Active Not Recruiting
A.C. Camargo Cancer Center São Paulo São Paulo Active Not Recruiting
HIAE - Hospital Israelita Albert Einstein São Paulo São Paulo Active Not Recruiting
Centro Oncológico Internacional (COI) Mexico City Mexico City Active Not Recruiting
INCan - Instituto Nacional de Cancerología Mexico City Mexico City Active Not Recruiting
Oncosalud AUNA Lima Lima Province Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07192991 on ClinicalTrials.gov ↗ ← All trials in Brazil